In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026

体外診断/IVDの世界市場予測(~2026):製品・サービス別、技術別、用途別、エンドユーザー別(病院)

◆タイトル:In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026
◆商品コード:MD3609-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年3月9日
◆ページ数:415
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥633,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥851,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,043,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界の体外診断/IVD市場規模が、2021年982億ドルから2026年1,131億ドルまで年平均2.9%成長すると予測しています。本調査レポートは、体外診断/IVDの世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業インサイト、製品・サービス別(試薬&キット、機器、データ管理ソフトウェア、サービス)分析、技術別(イムノアッセイ、臨床化学、分子診断、血液、微生物)分析、用途別(糖尿病、腫瘍、心臓病、薬物検査/薬理ゲノミクス、その他)分析、エンドユーザー別(病院、臨床研究室、POC検査センター、学術機関、その他)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・産業インサイト
・世界の体外診断/IVD市場規模:製品・サービス別(試薬&キット、機器、データ管理ソフトウェア、サービス)
・世界の体外診断/IVD市場規模:技術別(イムノアッセイ、臨床化学、分子診断、血液、微生物)
・世界の体外診断/IVD市場規模:用途別(糖尿病、腫瘍、心臓病、薬物検査/薬理ゲノミクス、その他)
・世界の体外診断/IVD市場規模:エンドユーザー別(病院、臨床研究室、POC検査センター、学術機関、その他)
・世界の体外診断/IVD市場規模:地域別
・競争状況
・企業情報

“The global IVD market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period.”
The growth of the IVD market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

“Reagents & kits segment accounted for the largest share in the IVD market.”
Based on product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of 68.1% of the IVD market in 2020. Accessibility to a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders in the early stages are expected to drive the growth of this segment.

“Oncology segment is expected to witness the fastest growth in the forecast period.”
Based on application, the IVD market is segmented into infectious diseases, diabetes, Oncology, cardiology, drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other applications. In 2020, infectious diseases accounted for 34.1% of the IVD market. The large share of this segment can be attributed to the rising prevalence of infectious diseases and multi-drug-resistant infectious diseases and the growing need for effective diagnostic tools for these diseases. However, the oncology segment is projected to grow at the highest CAGR of 6.6% during the forecast period. The increasing number of cancer cases across the globe, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth.

“Immunoassay/immunochemistry account for the largest share in the IVD market.”
Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis and other technologies. The immunoassay/immunochemistry segment accounted for 31% of the IVD technologies market in 2020. The growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy are contributing to the growth of this market segment.

“Hospital laboratories accounted for the largest share of IVD market in 2020”
Based on the end user, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2020, hospital laboratories accounted for the largest share of 47% of the IVD market, followed by clinical laboratories (23.8%) and POC testing centers (13%). Many diagnostic tests are carried out in hospitals. The acquisition of smaller physician practices and groups by hospitals is becoming a noticeable trend in the US healthcare industry; the continuation of this trend will support the IVD market for hospital laboratories.

“North America accounted for the largest share of the IVD market in 2020”
The IVD market is divided into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 39.8% of the IVD market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%), and the Middle East & Africa (2.9%). The IVD market in North America is well established, with the US being the major market in this region. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

A breakdown of the primary participants (supply-side) for the in vitro diagnostics market referred to for this report is provided below:
• By Company Type: Tier 1–34%, Tier 2–46%, and Tier 3–20%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–30%, Europe–45%, Asia Pacific–20%, Latin America- 3%, and Middle East and Africa– 2%

Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).

Research Coverage:
The market study covers the in vitro diagnostics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product and service, by technology, by application, by end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the in vitro diagnostics market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 42
1.1 OBJECTIVES OF THE STUDY 42
1.2 MARKET DEFINITION 42
1.2.1 INCLUSIONS AND EXCLUSIONS 42
1.3 MARKET SCOPE 43
FIGURE 1 IN VITRO DIAGNOSTICS MARKET SEGMENTATION 43
FIGURE 2 IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY 44
1.4 YEARS CONSIDERED FOR THE STUDY 44
1.5 CURRENCY 45
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 45
1.6 LIMITATIONS 45
1.7 STAKEHOLDERS 45
1.8 SUMMARY OF CHANGES 45
2 RESEARCH METHODOLOGY 47
2.1 RESEARCH APPROACH 47
FIGURE 3 RESEARCH DESIGN 47
2.1.1 SECONDARY RESEARCH 48
2.1.1.1 Key data from secondary sources 49
2.1.2 PRIMARY RESEARCH 49
2.1.3 PRIMARY SOURCES 49
FIGURE 4 KEY DATA FROM PRIMARY SOURCES 50
FIGURE 5 KEY INDUSTRY INSIGHTS 51
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 51
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 52
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 52
2.2 MARKET SIZE ESTIMATION 53
FIGURE 10 REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2020) 54
FIGURE 11 SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2020) 54
FIGURE 13 CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2021-2026) 57
FIGURE 14 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET 58
2.3 DATA TRIANGULATION APPROACH 59
2.4 MARKET SHARE ESTIMATION 60
2.5 ASSUMPTIONS FOR THE STUDY 60
2.6 LIMITATIONS 60
2.6.1 METHODOLOGY-RELATED LIMITATIONS 60
2.6.2 SCOPE-RELATED LIMITATIONS 61
2.7 RISK ASSESSMENT 61
TABLE 2 RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 66
4.1 IN VITRO DIAGNOSTICS MARKET OVERVIEW 66
4.2 ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2020) 67
4.3 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
4.4 GEOGRAPHIC MIX: IN VITRO DIAGNOSTICS MARKET 68
4.5 IN VITRO DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS 69
5 MARKET OVERVIEW 70
5.1 INTRODUCTION 70
5.2 MARKET DYNAMICS 70
FIGURE 25 IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 70
5.2.1 DRIVERS 71
5.2.1.1 Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases 71
TABLE 3 ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019–2050) 71
FIGURE 26 CHINA: NUMBER OF PEOPLE WITH DIABETES MELLITUS, 2000–2045 (IN MILLIONS) 72
5.2.1.2 Shift from centralized to point-of-care testing 72
5.2.1.3 Growing awareness and initiatives to increase healthcare accessibility in developing countries 72
5.2.1.4 Changing technological landscape 73
TABLE 4 IN VITRO DIAGNOSTICS MARKET: RECENT PRODUCT LAUNCHES 73
5.2.2 RESTRAINTS 74
5.2.2.1 Unfavorable reimbursement scenario 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 Development of disease-specific biomarkers and tests 74
TABLE 5 CANCER BIOMARKERS AND USES IN CLINICAL PRACTICE 74
5.2.3.2 Growing significance of companion diagnostics 75
5.2.3.3 Growth opportunities in emerging countries 75
FIGURE 27 ANNUAL PER CAPITA HEALTH EXPENDITURE IN DEVELOPING COUNTRIES, 2019 (USD MILLION) 76
5.2.4 CHALLENGES 76
5.2.4.1 Changing regulatory landscape in the EU 76
FIGURE 28 IVDR: KEY AREAS OF IMPACT 77
5.2.4.2 Operational barriers faced in conducting diagnostic tests 77
6 INDUSTRY INSIGHTS 78
6.1 INDUSTRY TRENDS 78
6.1.1 AUTOMATION OF CLINICAL LABORATORY TECHNIQUES 78
6.1.2 MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING 78
6.1.3 GROWING NUMBER OF REAGENT RENTAL AGREEMENTS 79
6.2 PORTER’S FIVE FORCES ANALYSIS 79
TABLE 6 PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET 79
6.2.1 INTENSITY OF COMPETITIVE RIVALRY 79
6.2.2 BARGAINING POWER OF SUPPLIERS 79
6.2.3 BARGAINING POWER OF BUYERS 80
6.2.4 THREAT OF NEW ENTRANTS 80
6.2.5 THREAT FROM SUBSTITUTES 80
6.3 REGULATORY ANALYSIS 80
6.3.1 US 80
TABLE 7 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES 80
FIGURE 29 US: REGULATORY PROCESS FOR IVD DEVICES 81
6.3.2 CANADA 82
FIGURE 30 CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA 82
6.3.3 EUROPE 83
TABLE 8 EUROPE: CLASSIFICATION OF IVD DEVICES 83
FIGURE 31 EUROPE: IVDR TIMELINE 83
6.3.4 JAPAN 84
FIGURE 32 REGULATORY PROCESS FOR IVD DEVICES IN JAPAN 84
TABLE 9 JAPAN: CLASSIFICATION OF IVD REAGENTS 84
TABLE 10 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
6.3.5 CHINA 85
TABLE 11 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85
6.3.6 INDIA 85
FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES 86
6.3.7 INDONESIA 86
TABLE 12 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES 87
6.3.8 RUSSIA 87
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES 87
6.3.9 SAUDI ARABIA 88
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88
6.3.10 MEXICO 88
FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES 88
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89

6.3.11 BRAZIL 89
FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES 90
6.3.12 SOUTH KOREA 90
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 90
6.4 PATENT ANALYSIS 91
FIGURE 36 TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2021) 91
FIGURE 37 PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2021) 92
6.5 TRADE ANALYSIS 92
6.5.1 TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS 92
TABLE 17 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (USD MILLION) 92
TABLE 18 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (TONS) 93
6.6 ECOSYSTEM ANALYSIS 93
FIGURE 38 ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET 93
6.7 VALUE CHAIN ANALYSIS 94
FIGURE 39 VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 94
6.8 SUPPLY CHAIN ANALYSIS 95
FIGURE 40 SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET 95
6.9 COVID-19 IMPACT ANALYSIS 96
6.9.1 COVID-19 HEALTH ASSESSMENT 96
6.9.2 COVID-19 ECONOMIC ASSESSMENT 96
6.9.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 96
FIGURE 41 CRITERIA IMPACTING THE GLOBAL ECONOMY 97
6.9.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE IN VITRO DIAGNOSTICS MARKET 98
FIGURE 42 COVID-19 IMPACT ON GLOBAL IN VITRO DIAGNOSTICS MARKET 98
FIGURE 43 ROCHE DIAGNOSTICS: IMPACT OF COVID-19 99
FIGURE 44 ABBOTT LABORATORIES, INC.: IMPACT OF COVID-19 99
6.10 PRICING ANALYSIS 100
TABLE 19 AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS 100
TABLE 20 AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS 100
TABLE 21 AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS 100
6.11 TECHNOLOGY ANALYSIS 101
6.11.1 KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 101
6.11.2 ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET 102
6.12 ADJACENT MARKET ANALYSIS 102
FIGURE 45 MICROFLUIDICS MARKET: MARKET OVERVIEW 103
6.13 CASE STUDY 104
FIGURE 46 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA 104
7 IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 105
7.1 INTRODUCTION 106
TABLE 22 IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 106
7.2 REAGENTS & KITS 106
7.2.1 TECHNOLOGICAL ADVANCES LIKE RAPID DIAGNOSTICS ARE EXPECTED TO BOOST THE GROWTH OF THIS SEGMENT 106
TABLE 23 IVD REAGENTS & KITS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 24 IVD REAGENTS & KITS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 108
7.3 INSTRUMENTS 108
TABLE 25 IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 26 IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 109
TABLE 27 IVD INSTRUMENTS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 110
7.3.1 FULLY AUTOMATED INSTRUMENTS 110
7.3.1.1 Rising incidence of various diseases and the increasing need to process heavy sample load to drive the market growth 110
TABLE 28 FULLY AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 111
7.3.2 SEMI-AUTOMATED INSTRUMENTS 111
7.3.2.1 Compact design and cost-effectiveness over automated analyzers are expected to increase the market growth of this segment 111
TABLE 29 SEMI-AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 112
7.3.3 OTHER INSTRUMENTS 112
TABLE 30 OTHER IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 113
7.4 DATA MANAGEMENT SOFTWARE 113
7.4.1 NEED FOR LABORATORY AUTOMATION DRIVES MARKET GROWTH 113
TABLE 31 KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN THE MARKET 114
TABLE 32 IVD DATA MANAGEMENT SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 115
TABLE 33 IVD DATA MANAGEMENT SOFTWARE MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 115
7.5 SERVICES 116
7.5.1 GROWING COMPETITIVENESS AND THE INCREASING NEED TO OFFER VALUE-ADDED SERVICES TO BOOST THE MARKET GROWTH 116
TABLE 34 IVD SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 35 IVD SERVICES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 117
8 IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY 118
8.1 INTRODUCTION 119
TABLE 36 IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 119
8.2 IMMUNOASSAY/IMMUNOCHEMISTRY 119
TABLE 37 IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE
IN THE MARKET 120
TABLE 38 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 39 IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE,
2019–2026 (USD MILLION) 121
8.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 122
TABLE 40 ELISA ANALYZERS AVAILABLE IN THE MARKET 122
TABLE 41 ELISA MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
TABLE 42 ELISA MARKET, BY TYPE, 2019–2026 (USD MILLION) 124
8.2.1.1 Chemiluminescence immunoassays 124
8.2.1.1.1 CLIAs hold the largest share of the ELISA market 124
TABLE 43 CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET 124
TABLE 44 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 125
8.2.1.2 Fluorescence immunoassays 126
8.2.1.2.1 Rapid processing, high sensitivity, and low cost have driven the adoption of FIAs 126
TABLE 45 FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET 126
TABLE 46 FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 127
8.2.1.3 Colorimetric immunoassays 127
8.2.1.3.1 Despite widespread use, demand for colorimetric immunoassays has declined due to low sensitivity 127
TABLE 47 COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET 128
TABLE 48 COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 128
8.2.2 RADIOIMMUNOASSAYS 129
8.2.2.1 Small sample volumes, rapid processing times offset by high cost and potential health hazards 129
TABLE 49 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 129
8.2.3 RAPID TESTS 130
8.2.3.1 COVID-19 pandemic drove demand for rapid tests 130
TABLE 50 RAPID TESTS AVAILABLE IN THE MARKET 130
TABLE 51 RAPID TESTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 131
8.2.4 WESTERN BLOTTING 131
8.2.4.1 Western blotting is the gold standard for result validation 131
TABLE 52 WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET 132
TABLE 53 WESTERN BLOTTING MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 132
8.2.5 ENZYME-LINKED IMMUNOSPOT ASSAYS 133
8.2.5.1 High sensitivity, functionality, and adaptability support the growth of ELISPOT 133
TABLE 54 ELISPOT ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 133
8.3 CLINICAL CHEMISTRY 134
TABLE 55 CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES 134
TABLE 56 CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES 135
TABLE 57 BLOOD GAS ANALYZERS AVAILABLE IN THE MARKET 136
TABLE 58 IVD MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY,
2019–2026 (USD MILLION) 137
TABLE 59 CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2026 (USD MILLION) 137
8.3.1 BASIC METABOLIC PANELS 138
8.3.1.1 Basic metabolic panels hold the largest share of the clinical chemistry market 138
TABLE 60 BASIC METABOLIC PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 138
8.3.2 LIVER PANELS 139
8.3.2.1 Growing liver disease burden and alcohol consumption driving market growth 139
TABLE 61 LIVER PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 139
8.3.3 RENAL PROFILES 140
8.3.3.1 Rising kidney disease prevalence ensures demand for renal profiles 140
TABLE 62 RENAL PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 140
8.3.4 LIPID PROFILES 141
8.3.4.1 Growth in CVD caseload supports the adoption of lipid panels 141
TABLE 63 LIPID PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 141
8.3.5 THYROID FUNCTION PANELS 142
8.3.5.1 Rising awareness and incidence of thyroid diseases drive the market 142
TABLE 64 THYROID FUNCTION PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 142
8.3.6 ELECTROLYTE PANELS 143
8.3.6.1 Focus on preventive healthcare to favor the market for electrolyte panels 143
TABLE 65 ELECTROLYTE PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 143
8.3.7 SPECIALTY CHEMICAL TESTS 144
8.3.7.1 Includes tests not prescribed regularly, such as protein tests, drugs-of-abuse tests, and therapeutic drug monitoring 144
TABLE 66 SPECIALTY CHEMICAL TESTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 144
8.4 MOLECULAR DIAGNOSTICS 145
TABLE 67 AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN THE MARKET 145
TABLE 68 IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION) 146
TABLE 69 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 147
8.4.1 POLYMERASE CHAIN REACTION 147
8.4.1.1 PCR dominates the molecular diagnostics market 147
TABLE 70 PCR INSTRUMENTS AVAILABLE IN THE MARKET 147
TABLE 71 PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 148
8.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY 148
8.4.2.1 Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth 148
TABLE 72 INAAT MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 149
8.4.3 HYBRIDIZATION 150
8.4.3.1 Advanced in hybridization and automation have driven the adoption of hybridization technologies 150
TABLE 73 HYBRIDIZATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 150
8.4.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING 151
8.4.4.1 Growing use in personalized medicine and declining costs 151
TABLE 74 NGS INSTRUMENTS AVAILABLE IN THE MARKET 151
TABLE 75 DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 152
8.4.5 MICROARRAYS 152
8.4.5.1 Advantages of microarrays—high throughput, resolution, and sensitivity—drive their adoption 152
TABLE 76 MICROARRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 153
8.4.6 OTHER MDX TECHNOLOGIES 154
TABLE 77 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 154
8.5 HEMATOLOGY 155
8.5.1 INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS IS EXPECTED TO DRIVE THE MARKET GROWTH 155
TABLE 78 HEMATOLOGY ANALYZERS AVAILABLE IN THE MARKET 155
TABLE 79 IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 156
8.6 MICROBIOLOGY 157
8.6.1 RISING PREVALENCE OF INFECTIOUS DISEASES WILL BOOST THE GROWTH OF THIS SEGMENT 157
TABLE 80 MICROBIOLOGY INSTRUMENTS AVAILABLE IN THE MARKET 157
TABLE 81 IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 158
8.7 COAGULATION & HEMOSTASIS 158
8.7.1 INCREASING NUMBER OF SURGERIES AND GROWING USE OF ANTICOAGULATION THERAPY WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT 158
TABLE 82 COAGULATION ANALYZERS AVAILABLE IN THE MARKET 159
TABLE 83 POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN THE MARKET 160
TABLE 84 IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2019–2026 (USD MILLION) 160
8.8 URINALYSIS 161
8.8.1 RISING PREVALENCE OF DIABETES AND KIDNEY DISORDERS WILL HAVE A POSITIVE IMPACT ON THE GROWTH OF THIS SEGMENT 161
TABLE 85 URINALYSIS INSTRUMENTS AVAILABLE IN THE MARKET 161
TABLE 86 IVD MARKET FOR URINALYSIS, BY COUNTRY, 2019–2026 (USD MILLION) 162
8.9 OTHER TECHNOLOGIES 162
TABLE 87 BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN THE MARKET 163
TABLE 88 TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN THE MARKET 163
TABLE 89 IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2019–2026 (USD MILLION) 164
9 IN VITRO DIAGNOSTICS MARKET, BY APPLICATION 165
9.1 INTRODUCTION 166
TABLE 90 IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 166
9.2 INFECTIOUS DISEASES 166
9.2.1 INFECTIOUS DISEASES ACCOUNTED FOR THE LARGEST MARKET
SHARE IN 2020 166
TABLE 91 IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 167
9.3 DIABETES 167
9.3.1 DIABETES PATIENTS REQUIRE CONSTANT MONITORING 167
TABLE 92 GLOBAL DIABETIC PATIENT POPULATION, 2019 VS. 2030 (MILLION) 168
TABLE 93 IVD MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION) 168
9.4 ONCOLOGY 169
9.4.1 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS WILL AID THE EARLY DIAGNOSIS OF CANCER 169
TABLE 94 IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 170
9.5 CARDIOLOGY 170
9.5.1 INCREASING DISEASE BURGEN OF CVD TO DRIVE THE MARKET GROWTH 170
TABLE 95 IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 170
9.6 DRUG TESTING/PHARMACOGENOMICS 171
9.6.1 INCREASING CONSUMPTION OF ILLICIT DRUGS WILL LEAD TO AN INCREASE IN TOXICOLOGY TESTING 171
TABLE 96 IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2019–2026 (USD MILLION) 172
9.7 HIV/AIDS 172
9.7.1 HIGH PREVALENCE OF AIDS IS EXPECTED TO BOOST THE MARKET GROWTH 172
TABLE 97 IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2019–2026 (USD MILLION) 173
9.8 AUTOIMMUNE DISEASES 173
9.8.1 DEVELOPMENT OF NOVEL DISEASE-SPECIFIC BIOMARKERS WILL HAVE A POSITIVE IMPACT ON THE MARKET GROWTH 173
TABLE 98 IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2019–2026 (USD MILLION) 174
9.9 NEPHROLOGY 174
9.9.1 INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT 174
TABLE 99 IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 175
9.10 OTHER APPLICATIONS 175
9.10.1 INCREASING DEMAND FOR SELF-MONITORING KITS IS LIKELY TO HAVE A POSITIVE IMPACT ON THE MARKET GROWTH 175
TABLE 100 IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2019–2026 (USD MILLION) 176

10 IN VITRO DIAGNOSTICS MARKET, BY END USER 177
10.1 INTRODUCTION 178
TABLE 101 IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 178
10.2 HOSPITAL LABORATORIES 178
10.2.1 GROWING PATIENT POPULATION AND REIMBURSEMENT POLICIES FOR DIAGNOSTIC TESTS WILL DRIVE THE MARKET GROWTH 178
TABLE 102 IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2019–2026 (USD MILLION) 179
10.3 CLINICAL LABORATORIES 179
TABLE 103 IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 180
TABLE 104 IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY
2019–2026 (USD MILLION) 180
10.3.1 LARGE/REFERENCE LABORATORIES 181
10.3.1.1 Rising infectious disease burden and demand for larger testing capacities will drive the growth of this segment 181
TABLE 105 LARGE/REFERENCE LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 181
10.3.2 MEDIUM-SIZED LABORATORIES 182
10.3.2.1 Increasing use of automated instruments to drive market growth 182
TABLE 106 MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 182
10.3.3 SMALL LABORATORIES 182
10.3.3.1 Increasing adoption of semi-automated instruments and low-end point-of-care devices will boost segment growth 182
TABLE 107 SMALL LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 183
10.4 POINT-OF-CARE TESTING CENTERS 183
10.4.1 GROWING USE OF POC DEVICES IN HOSPITALS AND CLINICAL LABORATORIES IS EXPECTED TO PROPEL THE GROWTH OF THIS SEGMENT 183
TABLE 108 IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY,
2019–2026 (USD MILLION) 184
10.5 PATIENTS 184
10.5.1 INCREASING ADOPTION OF PATIENT SELF-TESTING KITS TO DRIVE THE MARKET GROWTH 184
TABLE 109 IVD MARKET FOR PATIENTS, BY COUNTRY, 2019–2026 (USD MILLION) 185
10.6 ACADEMIC INSTITUTES 185
10.6.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT SUPPORTS MARKET GROWTH 185
TABLE 110 IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION) 186
10.7 OTHER END USERS 186
TABLE 111 IVD MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION) 187

11 IN VITRO DIAGNOSTICS MARKET, BY REGION 188
11.1 INTRODUCTION 189
TABLE 112 IVD MARKET, BY REGION, 2019–2026 (USD MILLION) 189
11.2 NORTH AMERICA 189
FIGURE 47 NORTH AMERICA: IVD MARKET SNAPSHOT 190
TABLE 113 NORTH AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 190
TABLE 114 NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 191
TABLE 115 NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 191
TABLE 116 NORTH AMERICA: IVD MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 191
TABLE 117 NORTH AMERICA: IVD MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 192
TABLE 118 NORTH AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 192
TABLE 119 NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 193
11.2.1 US 193
11.2.1.1 The US dominates the North American Market 193
TABLE 120 US: MACROECONOMIC INDICATORS 194
TABLE 121 US: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 194
TABLE 122 US: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 194
TABLE 123 US: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 195
TABLE 124 US: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 195
TABLE 125 US: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 196
TABLE 126 US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 196
11.2.2 CANADA 196
11.2.2.1 Increasing prevalence of chronic illness and implementation of favorable government initiatives drive the market in Canada 196
TABLE 127 CANADA: ESTIMATED PREVALENCE OF DIABETES 197
TABLE 128 CANADA: MACROECONOMIC INDICATORS 197
TABLE 129 CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 198
TABLE 130 CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 198
TABLE 131 CANADA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 198
TABLE 132 CANADA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 199
TABLE 133 CANADA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 199
TABLE 134 CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 200
11.3 EUROPE 200
TABLE 135 EUROPE: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 201
TABLE 136 EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 201
TABLE 137 EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 202
TABLE 138 EUROPE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 202
TABLE 139 EUROPE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 203
TABLE 140 EUROPE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 203
TABLE 141 EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 203
11.3.1 GERMANY 204
11.3.1.1 Increasing healthcare expenditure to drive the market growth in Germany 204
TABLE 142 GERMANY: MACROECONOMIC INDICATORS 204
TABLE 143 GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 204
TABLE 144 GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 205
TABLE 145 GERMANY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 205
TABLE 146 GERMANY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 206
TABLE 147 GERMANY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 206
TABLE 148 GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 207
11.3.2 FRANCE 207
11.3.2.1 Rising R&D Expenditure in France to drive market growth 207
TABLE 149 FRANCE: MACROECONOMIC INDICATORS 207
TABLE 150 FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 208
TABLE 151 FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 208
TABLE 152 FRANCE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 208
TABLE 153 FRANCE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 209
TABLE 154 FRANCE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 209
TABLE 155 FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 210
11.3.3 UK 210
11.3.3.1 The increasing number of accredited diagnostic laboratories propels market growth for in vitro diagnostics in the UK 210
TABLE 156 UK: MACROECONOMIC INDICATORS 211
TABLE 157 UK: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 211
TABLE 158 UK: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 211
TABLE 159 UK: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 212
TABLE 160 UK: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 212
TABLE 161 UK: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 213
TABLE 162 UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 213
11.3.4 ITALY 213
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth in Italy 213
TABLE 163 ITALY: MACROECONOMIC INDICATORS 214
TABLE 164 ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 214
TABLE 165 ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 214
TABLE 166 ITALY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 215
TABLE 167 ITALY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 215
TABLE 168 ITALY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 216
TABLE 169 ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 216
11.3.5 SPAIN 216
11.3.5.1 Growth of the geriatric population and rising demand for testing support the market in Spain 216
TABLE 170 SPAIN: MACROECONOMIC INDICATORS 217
TABLE 171 SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 217
TABLE 172 SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 217
TABLE 173 SPAIN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 218
TABLE 174 SPAIN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 218
TABLE 175 SPAIN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 219
TABLE 176 SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 219
11.3.6 RUSSIA 219
11.3.6.1 Increasing access to quality healthcare will support market growth in Russia 219
TABLE 177 RUSSIA: MACROECONOMIC INDICATORS 220
TABLE 178 RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 220
TABLE 179 RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 220
TABLE 180 RUSSIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 221
TABLE 181 RUSSIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 221
TABLE 182 RUSSIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 222
TABLE 183 RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 222
11.3.7 REST OF EUROPE 222
TABLE 184 ROE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 223
TABLE 185 ROE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 223
TABLE 186 ROE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 223
TABLE 187 ROE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 224
TABLE 188 ROE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 224
TABLE 189 ROE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 225
11.4 ASIA PACIFIC 225
FIGURE 48 ASIA PACIFIC: IVD MARKET SNAPSHOT 226
TABLE 190 ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 227
TABLE 191 ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 227
TABLE 192 ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 227
TABLE 193 ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 228
TABLE 194 ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 229
TABLE 195 ASIA PACIFIC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 229
TABLE 196 ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 230
11.4.1 JAPAN 230
11.4.1.1 Universal healthcare reimbursement policy to drive market
growth in Japan 230
TABLE 197 JAPAN: MACROECONOMIC INDICATORS 231
TABLE 198 JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 231
TABLE 199 JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 231
TABLE 200 JAPAN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 232
TABLE 201 JAPAN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 232
TABLE 202 JAPAN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 233
TABLE 203 JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 233
11.4.2 CHINA 233
11.4.2.1 Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth 233
TABLE 204 CHINA: MACROECONOMIC INDICATORS 234
TABLE 205 CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 234
TABLE 206 CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 234
TABLE 207 CHINA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 235
TABLE 208 CHINA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 235
TABLE 209 CHINA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 236
TABLE 210 CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 236
11.4.3 INDIA 236
11.4.3.1 Increasing private & public investments in the country’s healthcare system will drive market growth 236
TABLE 211 INDIA: MACROECONOMIC INDICATORS 237
TABLE 212 INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 237
TABLE 213 INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 237
TABLE 214 INDIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 238
TABLE 215 INDIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 238
TABLE 216 INDIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 239
TABLE 217 INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 239
11.4.4 SOUTH KOREA 239
11.4.4.1 Increased geriatric population coupled with a parallel increase in chronic illnesses to drive the market growth 239
TABLE 218 SOUTH KOREA: MACROECONOMIC INDICATORS 240
TABLE 219 SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 240
TABLE 220 SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 240
TABLE 221 SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 241
TABLE 222 SOUTH KOREA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 241
TABLE 223 SOUTH KOREA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 242
TABLE 224 SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 242
11.4.5 INDONESIA 242
11.4.5.1 Increasing insurance penetration and rising burden of infectious diseases to drive market growth 242
TABLE 225 INDONESIA: MACROECONOMIC INDICATORS 243
TABLE 226 INDONESIA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 243
TABLE 227 INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 243
TABLE 228 INDONESIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 244
TABLE 229 INDONESIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 244
TABLE 230 INDONESIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 245
TABLE 231 INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 245
11.4.6 REST OF ASIA PACIFIC 245
TABLE 232 ROAPAC: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 246
TABLE 233 ROAPAC: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 246
TABLE 234 ROAPAC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 246
TABLE 235 ROAPAC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 247
TABLE 236 ROAPAC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 247
TABLE 237 ROAPAC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 248

11.5 LATIN AMERICA 248
TABLE 238 LATIN AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 248
TABLE 239 LATIN AMERICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 249
TABLE 240 LATIN AMERICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 249
TABLE 241 LATIN AMERICA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 249
TABLE 242 LATIN AMERICA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 250
TABLE 243 LATIN AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 250
TABLE 244 LATIN AMERICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 251
11.5.1 BRAZIL 251
11.5.1.1 Improving healthcare infrastructure in Brazil to drive the growth of the IVD market 251
TABLE 245 BRAZIL: MACROECONOMIC INDICATORS 252
TABLE 246 BRAZIL: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 252
TABLE 247 BRAZIL: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 252
TABLE 248 BRAZIL: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 253
TABLE 249 BRAZIL: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 253
TABLE 250 BRAZIL: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 254
TABLE 251 BRAZIL: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 254
11.5.2 MEXICO 254
11.5.2.1 Improving accessibility and affordability of healthcare services to drive market growth for in vitro diagnostics 254
TABLE 252 MEXICO: MACROECONOMIC INDICATORS 255
TABLE 253 MEXICO: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 255
TABLE 254 MEXICO: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 255
TABLE 255 MEXICO: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 256
TABLE 256 MEXICO: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 256
TABLE 257 MEXICO: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 257
TABLE 258 MEXICO: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 257
11.5.3 REST OF LATIN AMERICA 257
TABLE 259 ROLA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 258
TABLE 260 ROLA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 258
TABLE 261 ROLA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 258
TABLE 262 ROLA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 259
TABLE 263 ROLA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 259
TABLE 264 ROLA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 260
11.6 MIDDLE EAST & AFRICA 260
TABLE 265 MIDDLE EAST & AFRICA: IVD MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 260
TABLE 266 MIDDLE EAST & AFRICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 261
TABLE 267 MIDDLE EAST & AFRICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 261
TABLE 268 MIDDLE EAST & AFRICA: IVD MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 261
TABLE 269 MIDDLE EAST & AFRICA: IVD MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 262
TABLE 270 MIDDLE EAST & AFRICA: IVD MARKET, BY END USER,
2019–2026 (USD MILLION) 262
TABLE 271 MIDDLE EAST & AFRICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION) 263
11.6.1 SAUDI ARABIA 263
11.6.1.1 High incidence of lifestyle diseases coupled with increasing healthcare budget is to drive market growth 263
TABLE 272 SAUDI ARABIA: MACROECONOMIC INDICATORS 263
TABLE 273 SAUDI ARABIA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION) 264
TABLE 274 SAUDI ARABIA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION) 264
TABLE 275 SAUDI ARABIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 264
TABLE 276 SAUDI ARABIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 265
TABLE 277 SAUDI ARABIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 265
TABLE 278 SAUDI ARABIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 266
11.6.2 REST OF MIDDLE EAST & AFRICA 266
TABLE 279 ROMEA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION) 266
TABLE 280 ROMEA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION) 267
TABLE 281 ROMEA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 267
TABLE 282 ROMEA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 268
TABLE 283 ROMEA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION) 268
TABLE 284 ROMEA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION) 269
12 COMPETITIVE LANDSCAPE 270
12.1 OVERVIEW 270
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 270
12.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE IN VITRO DIAGNOSTICS MARKET 272
12.4 MARKET SHARE ANALYSIS 273
TABLE 285 IN VITRO DIAGNOSTICS MARKET: DEGREE OF COMPETITION 273
12.4.1 MARKET SHARE ANALYSIS, BY TECHNOLOGY 275
12.4.1.1 Clinical chemistry 275
FIGURE 52 CLINICAL CHEMISTRY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 275
12.4.1.2 Immunochemistry/immunoassay analyzers 275
FIGURE 53 IMMUNOASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 275
12.4.1.3 Microbiology 276
FIGURE 54 MICROBIOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 276
12.4.1.4 Molecular diagnostics 276
FIGURE 55 MOLECULAR DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 276
12.4.1.5 Hematology 277
FIGURE 56 HEMATOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 277
12.4.1.6 Coagulation & hemostasis 277
FIGURE 57 COAGULATION & HEMOSTASIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 277
12.4.1.7 Urinalysis 278
FIGURE 58 URINALYSIS MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 278
12.5 R&D ASSESSMENT OF KEY PLAYERS 278
12.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 279
FIGURE 59 IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC REVENUE MIX 279
12.7 COMPANY EVALUATION QUADRANT 280
12.7.1 STARS 280
12.7.2 PERVASIVE PLAYERS 280
12.7.3 EMERGING LEADERS 280
12.7.4 PARTICIPANTS 280
FIGURE 60 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX, 2020 281
12.8 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS 282
12.8.1 PROGRESSIVE COMPANIES 282
12.8.2 DYNAMIC COMPANIES 282
12.8.3 STARTING BLOCKS 282
12.8.4 RESPONSIVE COMPANIES 282
FIGURE 61 IN VITRO DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS 283
12.9 COMPETITIVE BENCHMARKING 284
TABLE 286 OVERALL COMPANY FOOTPRINT 284
TABLE 287 COMPANY FOOTPRINT: BY PRODUCT AND SERVICE 285
TABLE 288 COMPANY FOOTPRINT: BY TECHNOLOGY 286
TABLE 289 COMPANY FOOTPRINT: BY APPLICATION 287
TABLE 290 COMPANY FOOTPRINT: BY END USER 288
12.10 COMPETITIVE SCENARIO 290
12.10.1 PRODUCT LAUNCHES & APPROVALS 290
TABLE 291 PRODUCT LAUNCHES & APPROVALS, 2020–2022 290
12.10.2 DEALS 291
TABLE 292 DEALS, 2021 291
12.10.3 OTHER DEVELOPMENTS 291
TABLE 293 OTHER DEVELOPMENTS, 2021 291
13 COMPANY PROFILES 292
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS 292
13.1.1 ROCHE DIAGNOSTICS 292
TABLE 294 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 292
FIGURE 62 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020) 293
TABLE 295 PRODUCT LAUNCHES AND APPROVALS 297
TABLE 296 DEALS 300
13.1.2 DANAHER CORPORATION 303
TABLE 297 DANAHER CORPORATION: BUSINESS OVERVIEW 303
FIGURE 63 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 304
TABLE 298 DEALS 308
13.1.3 ABBOTT LABORATORIES, INC. 310
TABLE 299 ABBOTT LABORATORIES: BUSINESS OVERVIEW 310
FIGURE 64 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 311
TABLE 300 PRODUCT LAUNCHES AND APPROVALS 313
TABLE 301 DEALS 315
13.1.4 SIEMENS HEALTHINEERS 317
TABLE 302 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 317
FIGURE 65 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021) 318
TABLE 303 PRODUCT LAUNCHES AND APPROVALS 321
TABLE 304 DEALS 321
TABLE 305 OTHER DEVELOPMENTS 322
13.1.5 SYSMEX CORPORATION 324
TABLE 306 SYSMEX CORPORATION: BUSINESS OVERVIEW 324
FIGURE 66 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020) 325
TABLE 307 PRODUCT LAUNCHES AND APPROVALS 327
TABLE 308 DEALS 329
TABLE 309 OTHER DEVELOPMENTS 330
13.1.6 THERMO FISHER SCIENTIFIC, INC. 332
TABLE 310 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 332
FIGURE 67 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 333
TABLE 311 PRODUCT LAUNCHES AND APPROVALS 339
TABLE 312 DEALS 342
TABLE 313 OTHER DEVELOPMENTS 344
13.1.7 BECTON, DICKINSON AND COMPANY 345
TABLE 314 BD: BUSINESS OVERVIEW 345
FIGURE 68 BD: COMPANY SNAPSHOT (2021) 346
TABLE 315 PRODUCT LAUNCHES AND APPROVALS 349
TABLE 316 DEALS 350
13.1.8 BIOMÉRIEUX SA 351
TABLE 317 BIOMÉRIEUX SA: BUSINESS OVERVIEW 351
FIGURE 69 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2020) 352
TABLE 318 PRODUCT LAUNCHES AND APPROVALS 355
TABLE 319 DEALS 356
13.1.9 BIO-RAD LABORATORIES, INC. 357
TABLE 320 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 357
FIGURE 70 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 358
TABLE 321 PRODUCT LAUNCHES AND APPROVALS 363
TABLE 322 DEALS 363
13.1.10 JOHNSON & JOHNSON 365
TABLE 323 JOHNSON & JOHNSON: BUSINESS OVERVIEW 365
FIGURE 71 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020) 365
13.1.11 AGILENT TECHNOLOGIES, INC. 367
TABLE 324 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 367
FIGURE 72 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020) 368
TABLE 325 PRODUCT LAUNCHES AND APPROVALS 371
TABLE 326 DEALS 372
13.1.12 QIAGEN N.V. 374
TABLE 327 QIAGEN N.V.: BUSINESS OVERVIEW 374
FIGURE 73 QIAGEN N.V.: COMPANY SNAPSHOT (2020) 374
TABLE 328 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 378
TABLE 329 DEALS 380
TABLE 330 OTHER DEVELOPMENTS 381
13.1.13 QUIDEL CORPORATION 382
TABLE 331 QUIDEL CORPORATION: BUSINESS OVERVIEW 382
FIGURE 74 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020) 382
TABLE 332 PRODUCT LAUNCHES AND APPROVALS 383
TABLE 333 DEALS 384
TABLE 334 OTHER DEVELOPMENTS 385
13.1.14 DIASORIN S.P.A. 386
TABLE 335 DIASORIN S.P.A.: BUSINESS OVERVIEW 386
FIGURE 75 DIASORIN S.P.A.: COMPANY SNAPSHOT (2020) 387
TABLE 336 PRODUCT LAUNCHES AND APPROVALS 389
TABLE 337 DEALS 392
TABLE 338 OTHER DEVELOPMENTS 393
13.1.15 ILLUMINA, INC. 394
TABLE 339 ILLUMINA, INC.: BUSINESS OVERVIEW 394
FIGURE 76 ILLUMINA, INC.: COMPANY SNAPSHOT (2020) 394
TABLE 340 PRODUCT REGISTRATIONS, LAUNCHES, AND APPROVALS 396
TABLE 341 DEALS 397
TABLE 342 OTHER DEVELOPMENTS 398
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 399
13.2.1 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC 399
TABLE 343 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW 399
FIGURE 77 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2020) 400
13.2.2 PERKINELMER INC. 402
TABLE 344 PERKINELMER, INC.: BUSINESS OVERVIEW 402
FIGURE 78 PERKINELMER, INC.: COMPANY SNAPSHOT (2020) 403
13.2.3 CHEMBIO DIAGNOSTICS, INC. 405
TABLE 345 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW 405
FIGURE 79 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2020) 405
13.2.4 HOLOGIC, INC. 407
TABLE 346 HOLOGIC, INC.: BUSINESS OVERVIEW 407
FIGURE 80 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 407
13.2.5 SURMODICS, INC. 409
TABLE 347 SURMODICS, INC.: BUSINESS OVERVIEW 409
FIGURE 81 SURMODICS, INC.: COMPANY SNAPSHOT (2020) 409
13.2.6 SPEEDX PTY. LTD. 411
13.2.7 GENSPEED BIOTECH GMBH 412

13.2.8 ACCELERATE DIAGNOSTICS, INC. 413
13.2.9 MERCK KGAA 413
13.2.10 CARIS LIFE SCIENCES, INC. 416
14 APPENDIX 417
14.1 DISCUSSION GUIDE 417
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 423
14.3 AVAILABLE CUSTOMIZATIONS 425
14.4 RELATED REPORTS 425
14.5 AUTHOR DETAILS 426

★調査レポート[体外診断/IVDの世界市場予測(~2026):製品・サービス別、技術別、用途別、エンドユーザー別(病院)] ( In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026 / MD3609-22) 販売に関する免責事項
[体外診断/IVDの世界市場予測(~2026):製品・サービス別、技術別、用途別、エンドユーザー別(病院)] ( In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026 / MD3609-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆